Mawaddati Rahmi

Mawaddati Rahmi

Auto-generated profile, based on publicly available information

Mawaddati Rahmi

Affiliation Faculty of Pharmacy, Universitas Pancasila, Lenteng Agung, Jakarta Selatan, Indonesia

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 August 2021 in JMIR Public Health and Surveillance
Verified
Journal Article
Open access
EPElizabeth Pisani
Elizabeth Pisani
AHAmalia Hasnida
Amalia Hasnida
MRMawaddati Rahmi
Mawaddati Rahmi
MKMaarten Olivier Kok
Maarten Olivier Kok
SHSteven Harsono
Steven Harsono
YAYusi Anggriani
Yusi Anggriani
The World Health Organization and others warn that substandard and falsified medicines harm health and waste money, especially in low- and middle-income countries. However, no country has measured the market-wide extent of the problem, and no standardized methods exist to estimate the prevalence of either substandard or falsified medicines. This is, in part, because the task seems overwhelming; medicine markets are huge and diverse, and testing medicines is expensive. Many countries do operate some form of postmarket surveillance of medicine, but their methods and goals differ. There is currently no clear guidance on which surveillance method is most appropriate to meet specific public health goals. In this viewpoint, we aimed to discuss the utility of both case finding and risk-based sentinel surveillance for substandard and falsified medicines, linking each to specific public health goals. We posit that choosing the system most appropriate to the goal, as well as implementing it with a clear understanding of the factors driving the production and sale of substandard and falsified medicines, will allow for surveillance resources to be concentrated most efficiently. We adapted principles used for disease outbreak responses to suggest a case-finding system that uses secondary data to flag poor-quality medicines, proposing risk-based indicators that differ for substandard and falsified medicines. This system potentially offers a cost-effective way of identifying “cases” for market withdrawal, enhanced oversight, or another immediate response. We further proposed a risk-based sentinel surveillance system that concentrates resources on measuring the prevalence of substandard and falsified medicines in the risk clusters where they are most likely to be found. The sentinel surveillance system provides base data for a transparent, spreadsheet-based model for estimating the national prevalence of substandard and falsified medicines. The methods we proposed are based on ongoing work in Indonesia, a large and diverse middle-income country currently aiming to achieve universal health coverage. Both the case finding and the sentinel surveillance system are designed to be adaptable to other resource-constrained settings.

12 December 2024 in PLOS Global Public Health
Verified
Journal Article
Open access
PDF file
EPElizabeth Pisani
Elizabeth Pisani
ARAyu Rahmawati
Ayu Rahmawati
EMEsti Mulatsari
Esti Mulatsari
MRMawaddati Rahmi
Mawaddati Rahmi
WNWilliam Nathanial
William Nathanial
OGon behalf of the STARmeds Study Group
on behalf of the STARmeds Study Group
The World Health Organization warns that substandard and falsified medicines threaten public health in low- and middle-income countries. However, medicine quality surveys are often small and unrepresentative of the market, and the true scale of the problem remains unknown. We conducted a large field survey of essential medicines in Indonesia, and investigated how weighting survey results by market volume altered estimates of medicine quality. We collected 1274 samples of allopurinol, amlodipine, cefixime, amoxicillin and dexamethasone from the internet and a randomised sample of all outlet-types where medicines are sold or dispensed in seven districts across the world’s fourth most populous nation. We conducted compendial testing for identity, assay, dissolution and uniformity. Samples that failed any chemical test were considered substandard. We compared raw prevalence of substandard medicines with prevalence adjusted by the national sales volume of each brand, relative to its weight among survey samples. The weighted prevalence of substandard products was 4.4%, 47% lower than the raw estimate (8.2%). Only 0.5% of samples (unweighted 1.2%) deviated from permitted limits by more than 10%. More antibiotics failed testing than other medicines (weighted prevalence 8.5 vs 3.1; raw prevalence 13.6 vs 4.9, both p<0.000). We found no relationship between quality and price; branded status; public procurement status; or outlet type. In Indonesia, unweighted survey data appeared to substantially over-estimate the health threat posed by substandard or falsified medicines. The types of sampling bias that led to over-representation of poor quality products in our survey are also indicated in other published surveys, possibly exaggerating the scale of the threat to public health posed by substandard and falsified medicines globally. Weighting survey results by sales volume likely improves robustness of estimates of medicine quality measured in field surveys.

9 October 2023 in medRxiv
Verified
Preprint
Open access
PDF file
EPElizabeth Pisani
Elizabeth Pisani
ARAyu Rahmawati
Ayu Rahmawati
EMEsti Mulatsari
Esti Mulatsari
MRMawaddati Rahmi
Mawaddati Rahmi
WNWilliam Nathanial
William Nathanial
TGthe STARmeds Study Group.
the STARmeds Study Group.
Introduction Most substandard and falsified medicines are at best not optimally effective, and at worst fatal. While the World Health Organisation and others warn they are a major threat to public health in low and middle income countries, little is known about their true prevalence. Authors of meta-analyses universally warn that survey data are not generalisable, because of unrepresentative study designs and variations in medicines included; tests performed; reference standards and pharmacopeia used; and definitions used when translating multiple quality parameters into a single pass/fail measure. We hypothesised that weighting for sales volume of different products and brands would increase accuracy of estimates of medicine quality. Methods and Findings We collected samples of allopurinol, amlodipine, cefixime and dexamethasone, as well as amoxicillin in 2 formulations in seven districts across Indonesia, the world’s fourth most populous country. Outlets, including retail pharmacies, over the counter medicine shops, public and private hospitals, primary health centres, doctors and nurses were randomised. We also sampled from the internet. Retail samples were collected by mystery shoppers, other samples overtly. We tested 1274 samples for identity and assay, and all relevant samples for dissolution and uniformity of content, using USP reference standards and monographs. Samples that failed any laboratory test were considered out of specification. We calculated prevalence per product and brand, and weighted the results by the sales volume of each product, using sales data from IQVIA and the national public procurement system. The weighted prevalence of out-of-specification products was 4.9%, 40.3% lower than the raw estimate (8.2%). Antibiotics were more likely to be substandard (weighted prevalence 6.8 vs 3.1; raw prevalence 13.6 vs 4.9, p<0.000). There was no relationship between quality and any of the following: price; branded status; public procurement status; outlet type. Our estimate compared with the Indonesian medicine regulator’s estimate of 4.0%, calculated based on unweighted analysis of 13,539 samples of a wider variety of medicines, collected overtly nation-wide. Conclusions Where data are available, weighting survey results by sales volume is a cost-effective way of improving the accuracy of estimates of out-of-specification medicines measured in field surveys.

1 April 2021 in JMIR Preprints
Verified
Preprint
Open access
EPElizabeth Pisani
Elizabeth Pisani
AHAmalia Hasnida
Amalia Hasnida
MRMawaddati Rahmi
Mawaddati Rahmi
MKMaarten Olivier Kok
Maarten Olivier Kok
SHSteven Harsono
Steven Harsono
YAYusi Anggriani
Yusi Anggriani
UNSTRUCTURED The World Health Organization and others warn that substandard and falsified medicines harm health and waste money, especially in low- and middle-income countries. However, no country has measured the market-wide extent of the problem, and no standardized methods exist to estimate the prevalence of either substandard or falsified medicines. This is, in part, because the task seems overwhelming; medicine markets are huge and diverse, and testing medicines is expensive. Many countries do operate some form of postmarket surveillance of medicine, but their methods and goals differ. There is currently no clear guidance on which surveillance method is most appropriate to meet specific public health goals. In this viewpoint, we aimed to discuss the utility of both case finding and risk-based sentinel surveillance for substandard and falsified medicines, linking each to specific public health goals. We posit that choosing the system most appropriate to the goal, as well as implementing it with a clear understanding of the factors driving the production and sale of substandard and falsified medicines, will allow for surveillance resources to be concentrated most efficiently. We adapted principles used for disease outbreak responses to suggest a case-finding system that uses secondary data to flag poor-quality medicines, proposing risk-based indicators that differ for substandard and falsified medicines. This system potentially offers a cost-effective way of identifying “cases” for market withdrawal, enhanced oversight, or another immediate response. We further proposed a risk-based sentinel surveillance system that concentrates resources on measuring the prevalence of substandard and falsified medicines in the risk clusters where they are most likely to be found. The sentinel surveillance system provides base data for a transparent, spreadsheet-based model for estimating the national prevalence of substandard and falsified medicines. The methods we proposed are based on ongoing work in Indonesia, a large and diverse middle-income country currently aiming to achieve universal health coverage. Both the case finding and the sentinel surveillance system are designed to be adaptable to other resource-constrained settings.

20 May 2024 in JMIR Preprints
Verified
Preprint
Open access
MRMawaddati Rahmi
Mawaddati Rahmi
WNWilliam Nathanial
William Nathanial
SASara Valente de Almeida
Sara Valente de Almeida
SKSondang Khairani
Sondang Khairani
HRHesty Utami Ramadaniati
Hesty Utami Ramadaniati
EPElizabeth Pisani
Elizabeth Pisani
BACKGROUND People buy medicines online for various reasons, such as convenience and cost savings. In Indonesia, the Ministry of Health allows registered platforms to sell medicines online; however, unregistered sellers are still widely circulated. While numerous studies have highlighted the quality of online medicines, comparisons with medicines purchased from licensed physical pharmacies are rare. OBJECTIVE To explore the conveniences of buying medicine online on several online platforms in Indonesia, investigate the quality, and compare the price and quality of medicine bought online to medicine purchased in physical pharmacies. METHODS The online sellers were categorised by regulatory status, and the conveniences of each were explored. Between February and May 2022, samples were collected from 732 physical pharmacies and 328 online platforms. Quality and price comparisons were conducted across different types of medicine sellers. RESULTS Obtaining samples from other online sellers was not always easy. Some platforms have complex registration processes, and we found locating unregulated sellers challenging. Notably, 58.8% of sampled medicines exceeded the median retail price from physical pharmacies for the same dose and form. Branded generic medicines exhibited the widest price variation, ranging from 0.15 to 16.4 times the median offline retail price, while generic medicines ranged from 0.18 to 4.1 times. Regarding quality, the failure rates were 7.9% online and 8.7% offline, showing no significant difference. Among online sellers, unregulated ones had a higher failure rate (11.2%) compared to regulated (3.0%) and semi-regulated (4.5%) sellers. Antibiotics were 2.6 times more likely to fail quality tests than other medicines (13.8% vs. 5.1%). CONCLUSIONS The conveniences of purchasing medicine online vary among sellers, and prices are not consistently lower than offline sellers. In terms of quality, as long as patients buy medicine online from regulated sellers, they don’t have to worry about the quality of medicines.